| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 76 | Solid growth + reasonable forward valuation; beta-dampened volatility | 6-12M |
| SA Quality/Value Composite | B | 73 | 16.3% YoY revenue growth, 19.9% EPS growth; forward PE 23.2x (fair for healthcare SaaS) | 6-12M |
| Zacks Earnings Momentum | A− | 82 | EPS growth 19.9% YoY; PEG 1.89 indicates modest upside to growth assumptions | 3-6M |
| Institutional & Smart Money Flow | B+ | 74 | YTD −22.9%; recent +2.0% intraday recovery; volume/float data constrained | 1-3M |
| Growth Sustainability & Moat | B | 72 | Hyper-growth flag active; healthcare SaaS segment resilient; moat qualitative only | 6-12M |
| Valuation & Safety (Pre-Penalty) | B | 75 | Current PE 37.6x (elevated); forward PE 23.2x (normalized); not overvalued vs. growth | 6-12M |
| Penalty Overlay | −2 | −2 | YTD drawdown −23%; elevated current PE; earnings date not disclosed | 1-3M |
| Confidence Score | B+ | 77 | Strong core metrics; data gaps on earnings schedule & balance sheet ratios | 3-6M |
| Volatility & Drawdown Risk | A− | 81 | Beta 0.88 (defensive); 52W range $148–$310; currently near mid-range | 6-12M |
| Crowding Risk Flag | MODERATE | 62 | Healthcare SaaS crowded; VEEV market-cap $34.2B (large-cap); YTD volatility evident | 3-6M |
Veeva Systems (VEEV) operates in the Health Care SaaS segment, competing against established players (e.g., Salesforce Health Cloud, Oracle Health, Infor CloudSuite) in life sciences, pharma, and medical device compliance/regulatory software. VEEV's $34.2B market cap positions it as a mid-large-cap leader within the specialized healthcare vertical SaaS category. The 16.3% YoY revenue growth and 19.9% EPS growth outpace broader SaaS indices (which averaged ~10–12% in mid-2026), signaling pricing power and operational leverage. However, the YTD −23% return reflects sector rotation out of high-multiple software names in a higher-rate environment. Forward PE of 23.2x is in-line with healthcare SaaS peers, whereas the trailing PE of 37.6x reflects earnings trough or temporary margin pressure.
| Risk Category | Severity | Mitigant / Context |
|---|---|---|
| Valuation Compression | MEDIUM | Trailing PE 37.6x is elevated; forward PE 23.2x is normalized. If rates stay elevated, multiple compression risk exists. Offset by 19.9% EPS growth and positive PEG 1.89. |
| Earnings Surprise Timing | MEDIUM | Earnings date not disclosed; creates binary event risk. Recommend hedging with limit orders around −5% to −8% levels. |
| Healthcare Sector Rotation | MEDIUM | YTD −23% reflects sector-wide software drawdown. VEEV's β=0.88 provides defensive hedge; fundamentals remain intact. |
| Balance Sheet Transparency | LOW | No TTM revenue or balance sheet ratios disclosed in live data. Qualitative assessment suggests typical SaaS strength (high gross margin, recurring ARR model). |
VEEV Analyst Price Target Forecast - ESEN Analytics
VEEV analyst price target: $254.6 average (range $205.0-$295.0), based on 42 Wall Street analysts.
ESEN AI Commentary: Analysts are diverging primarily on CRM platform competition and AI disruption risk: bulls believe Veeva's shift to convert key customers to its new CRM platform and AI roadmap updates position it favorably within regulated life sciences workflows, while bears worry Salesforce's competitive threat and AI disruption could pressure core subscription retention and margin assumptions, leading to the wide 35% spread between high and low targets.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
VEEV Systematic Research
Veeva Systems presents a distinctive financial profile within Health Care technology, characterized by debt-free operations and exceptional profitability metrics that systematic screening highlights as notable for enterprise software providers. The company maintains a D/E ratio of 0.0 with an unusually robust current ratio of 4.89, positioning balance sheet strength as a defining characteristic in the $33.1B market capitalization framework.
Profitability metrics demonstrate operational efficiency across multiple dimensions. The gross margin of 75.02% reflects strong pricing power in specialized cloud solutions, while the net margin of 28.37% indicates effective cost management. ROE of 13.36% and ROA of 11.01% suggest reasonable capital efficiency, though these figures trail some high-growth software peers. The P/E ratio of 35.15 trades at a meaningful discount to the 52-week high of $310.50, with current pricing at $203.78 representing a 34% pullback from peak valuations.
Key systematic screening observations include:
- Revenue growth of 16.25% YoY paired with accelerated EPS expansion of 19.92%, indicating margin improvement dynamics
- P/S ratio of 9.97 reflects premium valuation relative to software sector medians, justified by subscription revenue predictability
- Beta of 0.91 suggests lower volatility characteristics relative to broader equity markets
- Book value per share of $44.05 supports a P/B multiple of 4.63, representing intangible asset concentration typical of software platforms
Risk factors center on valuation sensitivity and competitive positioning against peers including Waystar (WAY), Doximity (DOCS), and Heartflow (HTFL). The model flags dependence on life sciences sector IT spending cycles as a fundamental consideration for revenue sustainability analysis.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.